TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$20 Million

Aptose Biosciences Inc

At-the-market Offering

Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm has CG-806, APTO-253 drugs in preclinical development stage pipeline.